Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 25, 2021Dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing positive results from first Phase 3 trial
-
Oct 22, 2021Pivotal trial met primary and all key secondary endpoints
-
Oct 20, 2021Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
-
Aug 30, 2021Dupixent rapidly improved symptoms after first dose, improving itch in one week and skin clearance in two weeks
-
Aug 6, 2021Approval is based on positive Phase 3 data demonstrating improvements in key disease burden measures and establishing its safety profile
-
Jun 28, 2021* Study also shows more people on Soliqua 100/33 had improved blood sugar control without weight gain and without low blood sugar events (hypoglycemia) in first head-to-head comparison with premixed insulin
-
Jun 28, 2021- Respiratory syncytial virus (RSV) is the leading cause of hospitalization in all infants1,2
-
Jun 17, 2021* $425 million investment in Sanofi's Swiftwater, PA facility expands production of Fluzone® High-Dose Quadrivalent for people 65 and older in the U.S.
-
Jun 1, 2021* This combination vaccine may simplify execution and reduce shots needed to complete CDC's recommended child and adolescent immunization schedule
-
May 17, 2021- Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a randomized Phase 3 trial, with potential to be best-in-class treatment for these patients
-
Apr 26, 2021Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants.1-5
-
Oct 21, 2020* $1 million in research funding to support PD GENEration, a first-of-its-kind national study offering free genetic testing and counseling for people with Parkinson's disease (PD)
-
Oct 13, 2020Data in children aged 6-11 further suggest Dupixent has potential to be best-in-class treatment option
-
Sep 14, 2020* Designation based on positive results from Part A of pivotal Phase 3 trial
-
Sep 9, 2020- New data on investigational brain-penetrant BTK inhibitor tolebrutinib (SAR442168) further support its potential in modulating disabling inflammatory processes within the central nervous system
-
Aug 17, 2020* Further strengthens core R&D areas of autoimmune and allergic diseases
-
Jul 31, 2020- Promising vaccine candidate selected by U.S. government’s Operation Warp Speed
-
Jul 30, 2020- Nirsevimab reduced respiratory syncytial virus (RSV) lower respiratory tract infections by 70 percent and related hospitalizations by 78 percent1
-
Jul 14, 2020* New alliance will use insights from translational and clinical studies to better identify targets, combinations and potential new indications for current medicines
-
Jun 19, 2020* Single-dose (300 mg) pre-filled pen provides additional administration option to adults and adolescents who are prescribed Dupixent
-
Jun 15, 2020- Preclinical data show anti-tumor activity in Sanofi's investigational compounds, including an oral selective estrogen receptor degrader (SERD) and an anti-CEACAM5 antibody-drug conjugate
-
Jun 14, 2020* Additional donation of factor therapy fulfills 2014 pledge to donate up to an unprecedented 1 billion IUs for humanitarian use
-
Jun 2, 2020Sarclisa added to carfilzomib and dexamethasone (Sarclisa combination) reduced risk of disease progression or death by 47% versus standard of care carfilzomib and dexamethasone (Kd) alone
-
May 29, 2020Across all groups combined, complete responses (CR) are now 16%; in the metastatic group with the longest follow-up, CRs are 20% representing a 200% increase over two years
-
May 26, 2020- In the pivotal trial, more than twice as many children achieved clear or almost clear skin and more than four times achieved itch reduction with Dupixent plus topical corticosteroids (TCS) compared to TCS alone
-
May 14, 2020Sutimlimab targets C1-activated hemolysis in cold agglutinin disease (CAD)
-
May 13, 2020- Emerging data demonstrate commitment to advancing cancer care, including two fully in-house investigational compounds: a potential best-in-class oral SERD for breast cancer and a first-in-class anti-CEACAM5 antibody-drug conjugate for non-small cell lung cancer
-
May 12, 2020- IKEMA trial results released early based on recommendation of an Independent Data Monitoring Committee
-
May 5, 2020Objective responses seen in 29% of patients with locally advanced basal cell carcinoma (BCC)
-
Apr 27, 2020- Libtayo decreased the risk of death by 32.4% compared to chemotherapy
-
Apr 27, 2020• Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced “critical” group with Kevzara higher-dose versus placebo and discontinuing less advanced “severe” group
-
Apr 24, 2020Latest innovation in quadrivalent meningococcal vaccination designed for use in persons 2 years of age and older in the U.S.
-
Apr 3, 2020- Detailed data to be presented at the Revolutionizing Atopic Dermatitis Conference show adding Dupixent to topical corticosteroids improved skin clearance; average overall disease improved by approximately 80%
-
Mar 16, 2020* U.S. Phase 2/3 trial initiated and will begin enrolling patients immediately
-
Mar 2, 2020* Sarclisa in combination with pomalidomide and dexamethasone (pom-dex) significantly reduced the risk of disease progression or death by 40% compared to pom-dex alone in a pivotal trial
-
Feb 18, 2020- Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi's well-established recombinant technology platform to expedite a potential COVID-19 vaccine
-
Jan 30, 2020- Acid sphingomyelinase deficiency (ASMD) is a rare, progressive and potentially life-threatening disease for which no treatments are approved
-
Jan 28, 2020If approved, Dupixent would be the first biologic medicine available in the U.S. for these children
-
Jan 23, 2020* Synthorx, Inc. is now a fully owned subsidiary of Sanofi
-
Dec 9, 2019- U.S.-based, state of the art facilities to be established for sustainable production of adjuvanted recombinant vaccine for use in the event of a pandemic
-
Nov 21, 2019- Sutimlimab, an investigational targeted C1s inhibitor, met its primary efficacy endpoint in Phase 3 trial for patients with cold agglutinin disease (CAD)
-
Nov 6, 2019*Oncology: New data from investigational isatuximab pivotal study for the treatment of relapsed/refractory multiple myeloma
-
Nov 4, 2019* Will be available in fall 2020, in time for the 2020-2021 flu season
-
Oct 9, 2019Add-on payment to provide additional Medicare reimbursement for Medicare patients prescribed Cablivi in eligible hospital inpatient settings
-
Sep 30, 2019- CARD is a treatment sequencing trial investigating the efficacy and safety of Jevtana versus abiraterone or enzalutamide after disease progression following initial androgen receptor-targeted agent therapy and docetaxel
-
Sep 18, 2019Understand AD program brings together a team of experts to help a teen with severe atopic dermatitis (AD) and his parents navigate the disease
-
Aug 28, 2019Court rules in favor of Sanofi and Regeneron in ongoing Praluent® (alirocumab) patent litigation
-
Aug 6, 2019U.S. FDA submission for children planned for 4Q 2019
-
Jun 26, 2019* First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP)
-
Jun 2, 2019News Summary: * Isatuximab, an investigational anti-CD38 monoclonal antibody, added to pomalidomide and dexamethasone prolonged progression free survival by 5 months compared to pomalidomide and dexamethasone alone (11.53 vs. 6.47 months, p=0.001, HR 0.596) * Overall response rate significantly greater with isatuximab combination therapy compared to pomalidomide and dexamethasone (60% vs. 35%, p<0.0001) * First positive randomized Phase 3 trial to evaluate an antibody in combination with pomalidomide and dexamethasone presented at this year’s ASCO annual meeting * European Medicines Agency accepted for review the Marketing Authorization Application for isatuximab
-
May 15, 2019- Pivotal Phase 3 data evaluated isatuximab (anti-CD38) in combination with pomalidomide/dexamethasone in prolonging progression-free survival in relapsed/refractory multiple myeloma
-
May 15, 2019* New data at ASCO include more than double the patients previously reported; median overall survival still not reached with a median follow-up of up to 17 months
-
May 7, 2019* Only biologic approved in the EU for severe asthma with type 2 inflammation, as characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO)
-
Apr 26, 2019* Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause
-
Apr 10, 2019* Sanofi continues its commitment to helping reduce cost burden for people living with diabetes with first-ever insulin savings program
-
Mar 11, 2019* Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis
-
Feb 27, 2019* Soliqua 100/33 now approved as an add-on to diet and exercise for adults with type 2 diabetes
-
Feb 25, 2019Praluent® (alirocumab) continues to be available in the U.S.
-
Feb 11, 2019* This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients
-
Feb 6, 2019- First medicine approved in the U.S. specifically for the treatment of aTTP, a rare blood-clotting disorder
-
Jan 23, 2019- The 0.5 mL dose is now approved for use in children 6 months through 35 months of age
-
Jan 14, 2019* First and only vaccine approved in the U.S. for repeat vaccination 8 years or more after the first vaccination to help protect against tetanus, diphtheria and pertussis, offering flexibility for health care providers to help manage their immunization schedules(2)
-
Jan 9, 2019-HERCULES Phase 3 trial met its primary endpoint, demonstrating that treatment with Cablivi resulted in a significantly faster time to platelet count response in patients with acquired thrombotic thrombocytopenic purpura (aTTP) when administered in conjunction with plasma exchange and immunosuppression
-
Nov 11, 2018* Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL
-
Nov 7, 2018* Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)
-
Oct 19, 2018-- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype
-
Oct 16, 2018- Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery
-
Sep 28, 2018* Libtayo is the third anti-PD-1 approved in the U.S.
-
Sep 12, 2018* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy
-
Jun 4, 2018-- Patients treated with cemiplimab experienced robust anti-tumor effects
-
May 21, 2018* In steroid-sparing VENTURE trial, Dupixent-treated patients substantially reduced use of oral corticosteroids, yet had fewer exacerbations and improved lung function compared to placebo.
-
May 16, 2018* U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018
-
May 1, 2018-- Agreement provides Praluent at lower net price and enables streamlined patient access based on physician attestation
-
Apr 25, 2018- If approved, health care professionals will be able to use the same 0.5 mL dose of Fluzone Quadrivalent vaccine with all patients ages 6 months and older for whom flu vaccination is recommended - which may provide more flexibility and convenience to immunizers.
-
Mar 27, 2018* Max SoloStar holds more insulin than any other long-acting insulin pen
-
Mar 27, 2018- Sanofi teams up with television personality Adam Savage and allergist Dr. Neeta Ogden to help dispel common allergy misconceptions with facts
-
Mar 10, 2018* Precision medicine approach will focus efforts on high-risk patients, such as those who have had heart attacks or unstable angina and cannot reduce their LDL-C below 100 mg/dL despite maximally-tolerated statins
-
Mar 10, 2018* ODYSSEY OUTCOMES trial met its primary endpoint, demonstrating that high-risk patients who added Praluent® (alirocumab) Injection to maximally-tolerated statins experienced significantly fewer major adverse cardiovascular events compared to those on maximally-tolerated statins alone
-
Jan 8, 2018Companies also announce submission of dupilumab supplemental BLA for uncontrolled, persistent asthma
-
Oct 31, 2017First study with a biologic to show benefit in severe steroid-dependent asthma population that enrolled patients regardless of blood eosinophil levels or any other Type 2 biomarkers at baseline
-
Oct 16, 2017- Late-breaking oral abstract presented at the World Congress of Gastroenterology -
-
Oct 5, 2017- Praluent continues to be available to patients in the U.S. -